{"id":169884,"date":"2024-07-23T02:43:21","date_gmt":"2024-07-23T06:43:21","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/transcode-therapeutics-inc-announces-pricing-of-public-offering\/"},"modified":"2024-08-18T11:48:41","modified_gmt":"2024-08-18T15:48:41","slug":"transcode-therapeutics-inc-announces-pricing-of-public-offering","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/transcode-therapeutics-inc-announces-pricing-of-public-offering.php","title":{"rendered":"TransCode Therapeutics, Inc. Announces Pricing of Public Offering"},"content":{"rendered":"<p><![CDATA[BOSTON, July  22, 2024  (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), (\u201cTransCode\u201d or the \u201cCompany\u201d), a clinical-stage RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced the pricing of a public offering of 10,000,000 shares of its common stock at a public offering price of $0.30 per share, for expected gross proceeds of $3,000,000, before deducting placement agent commissions and offering expenses. All of the shares of common stock are being offered by the Company. The offering is expected to close on July 24, 2024, subject to satisfaction of customary closing conditions.]]><\/p>\n<p>Read this article:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/07\/23\/2916919\/0\/en\/TransCode-Therapeutics-Inc-Announces-Pricing-of-Public-Offering.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"TransCode Therapeutics, Inc. Announces Pricing of Public Offering\">TransCode Therapeutics, Inc. Announces Pricing of Public Offering<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Read this article: TransCode Therapeutics, Inc. Announces Pricing of Public Offering <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/transcode-therapeutics-inc-announces-pricing-of-public-offering.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-169884","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/169884"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=169884"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/169884\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=169884"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=169884"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=169884"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}